Role of Pharmacogenetics in patients with alcoholic hepatitis
Not Applicable
- Conditions
- Health Condition 1: K701- Alcoholic hepatitis
- Registration Number
- CTRI/2021/04/032724
- Lead Sponsor
- SRM Medical College Hospital and Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Presentation with clinically diagnosed alcoholic hepatitis.
2. Maddreyâ??s discriminate function >32 (Used in corticosteroid therapy & identifying the Risk factors)
3. Lille score >0.45 ( Identification of responding to corticosteroid therapy after 1 week)
4. MELD Score ( Model of end stage live disease) >18 indicates SAH
Exclusion Criteria
Multi-organ Dysfunction,Uncontrolled infection,Patients with a serum creatine >500µmol/L or requiring renal support,Hepatocellular carcinoma,Pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the overall response rate (complete response +partial response) to Pharmacogenetic based prednisolone therapy in patients with previously untreated alcoholic hepatitis.Timepoint: first response rate can be measured at 1st week from the day of the therapy for 4 weeks
- Secondary Outcome Measures
Name Time Method To access the ADR in Alcoholic Hepatitis PatientsTimepoint: from 1st week to 4 th week measurment of ADRs were monitored.